Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Monday, June29

PO R S T B

12271 Determinants of failure of highly active antiretroviral therapy (HAART)
Ferdinand Wit; R. Van Leeuwen; GJ. Weverling; S.A. Danner; P. Reiss;
F. De Wolf;J.M.A. Lange, Netherlands
12272 Regional survival differences across Europe in HIV-positive patients
reflect differences in antiretroviral treatment. Data from the Eurosida
study group
Stefano Vella*; Antonio Chiesi; L.G. Dally; A. Macroft; A.N. Phillips;
V Miller; S. Stazewski;J.D. Kundgren, Italy
12273 Preliminary comparison of outcome in patients starting either ritonavir
(R), indinavir or saquinavir (S) in 1749 patients from the Eurosida study
lens d. Lundgren, Denmark
12274 Treatment of ritonavir (RTV)/saquinavir (SQV) versus RTV/SQV/stavudine
(d4T) (The Prometheus Study): Preliminary results
Elisabeth H. Gisolf*; F. de Wolf J. Pelgrom; F. van Wanzeele; M. Popescu;
A. Japour; S.A. Danner; R. van Leeuwen, The Netherlands
12275 Stavudine (d4T), nelfinavir (NFV) and nevirapine (NVP):Suppression of
HIV-1 RNA to fewer than 50 copies/ml during 5 months of therapy
Gail Skowron*; G. Leoung; B. Yen-Lie Berman; A. Dusek; R. Anderson;
R. Grosso; S. Beebe, USA
12276 Impact of HAART in a cohort of patients from the Basque country Spain)
Jose Antonio Iribarren*; Francisco Rodriguez-Arrondo;. Arrizabalaga; MA. Von Wichmann;X. Camino, Spain
12277 Importance of molecularflexibilityforthe resistance of HIV-1 protease
inhibitors
Ryohei Kato*; K. Yusa; S.V. Gulnik; T. Bhat; H. Hayashi; H. Mitsuya;
J.W Erickson, USA
12278 Improved survival among men and women on triple antiretroviral
therapy
Robert Hogg*; B. Yip; KJ.P. Craib; M.T. Schechter; M. V. O'Shaughnessy;
J.S.G. Montaner, Canada
12279 Two-year durability of HIV-1 load suppression in patients treated with
indinavir who experience virus load declines to <500 vRNA copies/ml
Daniel Holder*; M. Shivaprakash; W.A. Schleif;J.A. Chodakewitz;
J.H. Condra; E.A. Emini, USA
12280 Protease inhibitors are associated with declining AIDS deaths
in New York City (NYC)
Thomas Wong; A. Reggy; M.A. Chiasson; R. Simonds; V. Loo;J. Heffess,
USA
12281 Limited efficacy of nelfinavir afterfailure of other protease inhibitors (PI)
Cecile I. Poggi* A. Lafeuillade; G. Hittinger; L. Chollet; A. Rieu;
M.P. Pradie; N. Profizi, France
12282 Factors associated with progression to a new AIDS defining event or
death in patients receiving a protease inhibitor
Sophie Grabar*; D. Costagliola, France
12283 Effect of dose escalation on the safety,tolerability and efficacy of ritonavir
Geertrui van Hove*; Jose Ramon Arribas; A. Lazzarin; T. Martin;
M. Moroni; G. Vanhove; C MacLeod; The collaborative group on ritonavir
Dose Escalation (CGRDE)., USA
12284 HIV RNA load in blood and seminal plasma of patients recieving
antiretroviral therapy with protease inhibitors
Emmanuel Dulioust*; Anne Tachet des Combes; L. Finkielsztejn;

M. de Almeida; D. Salmon-Ceron; P. Jouannet; C. Rouzioux; D. Sicard,
France

12285 Salvage therapy with a combination including nelfinavir in patients
failing treatment including a protease inhibitor (PI)
Sharon Walmsley*; C Walach; A. Moses; I. Salit; A. Humar; D. Fletcher,
Canada
12286 Correlation between plasmatic levels of indinavir and inmunologic and
virologic parameters in HIV-patients
Anna Ochoa de Echaguen*; David Dalmau Juanola; M. Xercauins;
J. Vidal; X. Martinez; C. Sanchez; X. Garau, Spain
12287 Reversal of hyperlipidaemia and lipodystrophy in patients switching
therapy to nelfinavir
Chris Duncombe*; M. Bloch; D. Austin; D. Quan, Australia
12288 Hepatotoxicity after introduction of highly active antiretroviral therapy
(HAART)
Rafael Rodriguez-Rosado*; J. Garcia-Samaniego; V. Soriano; F. Muhoz;
J. Gonzalez-Lahoz, Spain
12289 Peptidic"tongs"constrained by a rigid spacer:A novel series
of dimerization HIV-1 protease inhibitors
Nicole Boggetto*; A. Bouras; E. De Rosny; Z. Benatalah;
M. Reboud-Ravaux; S. Sicsic, France
12290 Sixteen week follow-up of indinavir sulfate (IDV) administered Q8 hours
(H) versus Q12H in combination with efavirenz (EFV)
Robin Isaacs*; Diane Havlir; J. Pottage; J. Kahn; C. Shikuma;
D. Mehrotra; R. Isaacs, USA
12291 Protease inhibitors among injecting drug users in Amsterdam:
Cumulative incidence, determinants and impact
Janke Schinkel*; R.A. Coutinho; E.J.C. Van Ameijden, The Netherlands
12292 Effectiveness of a systematic educational approach to alter suboptimal
dosing of indinavir
Sarah Lewis*; Andrea Ho-Kean; L.K. Gajewski; G.J. Vanscoy, USA
12293 Persistent CD8+ T lymphocyte activation despite prolonged protease
inhibitor therapy suggests residual viral activity
Gilbert R. Kauffman*;J.Zaunders;A.D. Kelleher; C. Duncombe;A. Carr; D.A.
Cooper, Australia
12294 Virological response to protease inhibitors in an HIV clinic cohort
Schlomo Staszewski*; Andrew Phillips; V. Miller; CA. Sabin; A. Carlebach;
R. Brodt; A. Berger; A. Hill, Germany
NOTES

IUN

CONFERENCE WORKBOOK

33